Assessing Revolution Medicines (RVMD) Valuation After Positive RASolute 302 And Zoldonrasib Clinical Updates [Yahoo! Finance]
Revolution Medicines, Inc. (RVMD)
Company Research
Source: Yahoo! Finance
Clinical catalysts and pipeline momentum behind Revolution Medicines stock Revolution Medicines (RVMD) is in focus after reporting statistically significant Phase 3 RASolute 302 data for daraxonrasib in metastatic pancreatic cancer, alongside updated early stage results for zoldonrasib in KRAS G12D non small cell lung cancer. See our latest analysis for Revolution Medicines. Despite the latest 1 day share price return of negative 2.68% and a 7 day share price return of negative 9.96%, Revolution Medicines has a 30 day share price return of 42.33%, a year to date share price return of 66.63% and a 1 year total shareholder return of 217.51%. This suggests strong momentum around the recent daraxonrasib and zoldonrasib updates and growing attention on its late stage pipeline. If this kind of clinical news has your attention, it can be useful to see what else is moving in related areas, including 32 healthcare AI stocks With Revolution Medicines now a roughly US$28.5b pre-revenu
Show less
Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVMD alerts
High impacting Revolution Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
RVMD
News
- Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026GlobeNewswire
- Erasca Shares Plunge 48% After Trial Patient Death, Patent Dispute Emerges [Yahoo! Finance]Yahoo! Finance
- Revolution's on a pancreatic cancer winning streak. What comes next for the biotech? [Yahoo! Finance]Yahoo! Finance
- Erasca shares sink after patient death in early-stage cancer drug trial [Yahoo! Finance Canada]Yahoo! Finance Canada
- Pancreatic cancer patient Ben Sasse sees 'massive' tumor reduction with experimental new drug [FOX News]FOX News
RVMD
Earnings
- 2/25/26 - Miss
RVMD
Sec Filings
- 4/29/26 - Form 4
- 4/28/26 - Form DEFA14A
- 4/28/26 - Form ARS
- RVMD's page on the SEC website